We support reforms which will allow all Canadians to access the medicines they need when needed, equitably and consistently, as outlined in our core positions and principles, and in formal submissions.
National Strategy for High-Cost Drugs for Rare Diseases:
BMC’s Submission to the National Strategy for High-Cost Drugs for Rare Diseases Online Engagement (March 26, 2021)
Pharmacare Advisory Council:
BMC’s Position Points on Key Recommendations
Joint Discussion Paper:
Better Pharmacare For Patients: Evaluating Policy Options (Français)
We support a strong regulatory framework for pharmaceutical pricing which ensures value and an environment which delivers the best possible care for patients.
Input to PMPRB Regarding Proposed Guideline Revisions Related to Gap Medicines, Comparator Countries and International Price Tests
We a support a national regulatory framework which protects Canadian patients, including addressing supply issues like drug shortages which put patients at risk.
Submission to the Government of Canada’s biomanufacturing consultation (March 2021)
We seek pharmaceutical assessment which incorporates patient-driven evidence and perspectives and leads to improved patient care.